UCHL5 expression associates with improved survival in lymph-node-positive rectal cancer

Show full item record



Permalink

http://hdl.handle.net/10138/222497

Citation

Arpalahti , L , Hagstrom , J , Mustonen , H , Lundin , M , Haglund , C & Holmberg , C I 2017 , ' UCHL5 expression associates with improved survival in lymph-node-positive rectal cancer ' , Tumor Biology , vol. 39 , no. 7 . https://doi.org/10.1177/1010428317716078

Title: UCHL5 expression associates with improved survival in lymph-node-positive rectal cancer
Author: Arpalahti, Leena; Hagstrom, Jaana; Mustonen, Harri; Lundin, Mikael; Haglund, Caj; Holmberg, Carina I.
Contributor organization: Research Programs Unit
Translational Cancer Biology (TCB) Research Programme
University of Helsinki
Medicum
Clinicum
Department of Pathology
HUSLAB
Department of Surgery
II kirurgian klinikka
Institute for Molecular Medicine Finland
Johan Edvard Lundin / Principal Investigator
HUS Head and Neck Center
HUS Abdominal Center
Date: 2017-07-06
Language: eng
Number of pages: 8
Belongs to series: Tumor Biology
ISSN: 1010-4283
DOI: https://doi.org/10.1177/1010428317716078
URI: http://hdl.handle.net/10138/222497
Abstract: Colorectal cancer is among the three most common cancer types for both genders, with a rising global incidence. To date, prognostic evaluation is difficult and largely dependent on early detection and successful surgery. UCHL5/Uch37 is an integral part of the protein homeostasis network as one of the three deubiquitinating enzymes associated with the 26S proteasome. Here, we have investigated in colorectal cancer the possible association of UCHL5 tumor expression and patient survival. UCHL5 tumor expression was evaluated by immunohistochemistry in 779 surgically treated colorectal cancer patients from Helsinki University Hospital, Finland, with assessment of clinicopathological parameters and the effect of UCHL5 expression on patient survival. High and undetectable UCHL5 expression both correlated with increased overall disease-specific survival in the subgroup of patients with lymph-node-positive (Dukes C/stage III) rectal cancer. Within this subgroup of 105 stage-III rectal cancer patients, none of the 7 with high UCHL5 expression died of colorectal cancer within 10 years after surgery (p = 0.012). A similar, though less prominent, survival trend occurred throughout the whole patient cohort. In conclusion, UCHL5 is a promising novel prognostic marker in lymph-node-positive rectal cancer. Our results also advance the currently limited knowledge of biomarkers in colorectal cancer treatment.
Subject: Colorectal cancer
deubiquitination
prognosis
proteasome
UCHL5
DEUBIQUITINATING ENZYME UCH37
SMALL-MOLECULE INHIBITOR
PROTEASOME ACTIVITY
ACTIVATION
RESISTANCE
STRATEGY
USP14
3122 Cancers
Peer reviewed: Yes
Rights: cc_by_nc
Usage restriction: openAccess
Self-archived version: publishedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
1010428317716078.pdf 800.8Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record